carboprost ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 502 35700-23-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • carboprost
  • carboprost tromethamine
  • carboprost trometamol
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY.
  • Molecular weight: 368.51
  • Formula: C21H36O5
  • CLOGP: 2.67
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 97.99
  • ALOGS: -3.72
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.47 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility) 75 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Jan. 9, 1979 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G02AD04 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
UTEROTONICS
Prostaglandins
FDA CS M0017805 Prostaglandins
FDA EPC N0000175454 Prostaglandin Analog
CHEBI has role CHEBI:36063 oxytocic agents
CHEBI has role CHEBI:50691 abortifacient drug
MeSH PA D010120 Oxytocics
MeSH PA D012102 Reproductive Control Agents
MeSH PA D000019 Abortifacient Agents
MeSH PA D000020 Abortifacient Agents, Nonsteroidal

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postpartum hemorrhage indication 47821001
Pregnancy with abortive outcome indication 363681007
Incomplete miscarriage off-label use 156072005
Induction of labor off-label use 236958009
Cervical ripening procedure off-label use 236959001
Hydatidiform mole, benign off-label use 417044008
Hyperbilirubinemia contraindication 14783006 DOID:2741
Disorder of lung contraindication 19829001 DOID:850
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Third trimester pregnancy contraindication 41587001
Low blood pressure contraindication 45007003
Severe pre-eclampsia contraindication 46764007
Heart disease contraindication 56265001 DOID:114
Acute nephropathy contraindication 58574008
Diabetes mellitus contraindication 73211009 DOID:9351
Stenosis of cervix contraindication 83536006
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Asthma contraindication 195967001 DOID:2841
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Gynecological Surgery contraindication
Inflammatory Disease of Female Pelvic Organs contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.79 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin F2-alpha receptor GPCR AGONIST CHEMBL CHEMBL

External reference:

IDSource
4018095 VUID
N0000146433 NUI
D00682 KEGG_DRUG
58551-69-2 SECONDARY_CAS_RN
20259 RXNORM
C0007047 UMLSCUI
CHEBI:3403 CHEBI
CHEMBL1237122 ChEMBL_ID
CHEMBL1237105 ChEMBL_ID
D002260 MESH_DESCRIPTOR_UI
C062843 MESH_SUPPLEMENTAL_RECORD_UI
5281075 PUBCHEM_CID
4044 INN_ID
7B5032XT6O UNII
DB00429 DRUGBANK_ID
319432 MMSL
4358 MMSL
d00588 MMSL
109057004 SNOMEDCT_US
109058009 SNOMEDCT_US
373455002 SNOMEDCT_US
4018095 VANDF
4022193 VANDF
001310 NDDF
004942 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hemabate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0856 INJECTION, SOLUTION 250 ug INTRAMUSCULAR NDA 19 sections
Carboprost Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 43598-698 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 15 sections
CARBOPROST TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 43598-917 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 15 sections
CARBOPROST TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 43598-919 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 15 sections
CARBOPROST TROMETHAMINE Human Prescription Drug Label 1 55150-459 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 10 sections
CARBOPROST TROMETHAMINE Human Prescription Drug Label 1 62332-777 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 10 sections
CARBOPROST TROMETHAMINE Human Prescription Drug Label 1 65145-132 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 15 sections
CARBOPROST TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 65219-579 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 15 sections
carboprost tromethamine Human Prescription Drug Label 1 68083-584 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 16 sections
CARBOPROST TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 69784-240 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 19 sections
CARBOPROST TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 69784-240 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 19 sections
CARBOPROST TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 69784-240 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 19 sections
carboprost tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 70121-1680 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 15 sections
carboprost tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 70512-859 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 19 sections
CARBOPROST TROMETHAMINE Human Prescription Drug Label 1 71839-137 INJECTION, SOLUTION 250 ug INTRAMUSCULAR ANDA 9 sections
Carboprost Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 81298-5010 INJECTION 250 ug INTRAMUSCULAR ANDA 18 sections
Carboprost Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 81298-5010 INJECTION 250 ug INTRAMUSCULAR ANDA 18 sections